Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 18 Gastrointestinal 12 Genitourinary 6 Tumor-Agnostic 4 Head & Neck 3 Gynecologic 3 Thoracic 1 Lymphoid 1 Endocrine 1 Dermatologic 1 CNS 1

Conditions

Patient Participation 1 Melanoma 1

Interventions

pembrolizumab 339 Nivolumab 305 Ipilimumab 274 Cyclophosphamide 195 aldesleukin 148 Interleukin-2 110 fludarabine phosphate 107 trametinib 85 Temozolomide 83 fludarabine 81 Dacarbazine 81 dabrafenib 77 Radiotherapy 75 Biopsy 75 Vemurafenib 71 Imiquimod 53 Bevacizumab 51 sargramostim 50 Magnetic Resonance Spectroscopy 50 Specimen Handling 49 Radiosurgery 49 Peripheral Blood Stem Cell Transplantation 49 Paclitaxel 49 Aminolevulinic Acid 49 binimetinib 48 Carboplatin 48 Blood Specimen Collection 47 cemiplimab 46 Cisplatin 45 3-ingenyl angelate 45

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Decision Support Techniques × Dermatologic × Clear all

NCT04240717 2022-11-07

PEF-Immun

University Hospital Heidelberg

Phase NA Completed

Melanoma, Patient Participation

Data powered by HemOnc (CC BY 4.0) Colophon ⚡